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Abstract
Introduction: Progesterone receptors (PR) are emerging as important breast cancer drivers. Phosphorylation events
common to breast cancer cells impact PR transcriptional activity, in part by direct phosphorylation. PR-B but not
PR-A isoforms are phosphorylated on Ser294 by mitogen activated protein kinase (MAPK) and cyclin dependent
kinase 2 (CDK2). Phospho-Ser294 PRs are resistant to ligand-dependent Lys388 SUMOylation (that is, a repressive
modification). Antagonism of PR small ubiquitin-like modifier (SUMO)ylation by mitogenic protein kinases suggests
a mechanism for derepression (that is, transcriptional activation) of target genes. As a broad range of PR protein
expression is observed clinically, a PR gene signature would provide a valuable marker of PR contribution to early
breast cancer progression.
Methods: Global gene expression patterns were measured in T47D and MCF-7 breast cancer cells expressing
either wild-type (SUMOylation-capable) or K388R (SUMOylation-deficient) PRs and subjected to pathway analysis.
Gene sets were validated by RT-qPCR. Recruitment of coregulators and histone methylation levels were determined
by chromatin immunoprecipitation. Changes in cell proliferation and survival were determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and western blotting. Finally, human breast
tumor cohort datasets were probed to identify PR-associated gene signatures; metagene analysis was employed to
define survival rates in patients whose tumors express a PR gene signature.
Results: ’SUMO-sensitive’ PR target genes primarily include genes required for proliferative and pro-survival
signaling. DeSUMOylated K388R receptors are preferentially recruited to enhancer regions of derepressed genes
(that is, MSX2, RGS2, MAP1A, and PDK4) with the steroid receptor coactivator, CREB-(cAMP-response element-
binding protein)-binding protein (CBP), and mixed lineage leukemia 2 (MLL2), a histone methyltransferase mediator
of nucleosome remodeling. PR SUMOylation blocks these events, suggesting that SUMO modification of PR
prevents interactions with mediators of early chromatin remodeling at ‘closed’ enhancer regions. SUMO-deficient
(phospho-Ser294) PR gene signatures are significantly associated with human epidermal growth factor 2 (ERBB2)-
positive luminal breast tumors and predictive of early metastasis and shortened survival. Treatment with
antiprogestin or MEK inhibitor abrogated expression of SUMO-sensitive PR target-genes and inhibited proliferation
in BT-474 (estrogen receptor (ER)+/PR+/ERBB2+) breast cancer cells.
Conclusions: We conclude that reversible PR SUMOylation/deSUMOylation profoundly alters target gene selection
in breast cancer cells. Phosphorylation-induced PR deSUMOylation favors a permissive chromatin environment via
recruitment of CBP and MLL2. Patients whose ER+/PR+ tumors are driven by hyperactive (that is, derepressed)
phospho-PRs may benefit from endocrine (antiestrogen) therapies that contain an antiprogestin.
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Introduction
Breast cancer is the most commonly diagnosed cancer
in women, and the second leading cause of cancer-
related death [1]. The molecular factors driving its
initiation and progression are not completely under-
stood. A randomized clinical trial by the Women’s
Health Initiative (WHI) demonstrated that hormone
replacement therapy (HRT), containing estrogens and
progestins (but not estrogens alone), significantly
increased the risk of developing invasive breast cancer
in post-menopausal women [2,3]. A similar conclusion
was made from the Million Women observational study
[4]. These findings resulted in dramatically fewer pre-
scriptions for HRT and, as a result, breast cancer inci-
dence dropped considerably [5]. Further analysis of the
WHI data demonstrated that women prescribed HRT
containing estrogens alone experienced a reduced risk
of developing invasive breast cancer [3,6]. Progesterone
receptor (PR) expression is traditionally used as a clini-
cal indicator of estrogen receptor (ER) function (that is,
PR is an ER target gene). However, while controversial,
this surprising epidemiological evidence provides a
strong rationale for further investigation of the unique
actions of PRs as mediators of breast cancer initiation
and early progression (reviewed in [7]).
Classically, PRs are defined as ligand-activated tran-
scription factors that bind target gene promoters or
enhancers as dimers capable of recruiting coregulatory
molecules required for efficient transcription. More
recently, it has become well recognized that protein
kinases are rapidly activated by steroid hormones (as in
response to peptide growth factors). Indeed, phosphory-
lation events provide key regulatory inputs to PR action
(reviewed in [8] and discussed below). A few mutations
in PR have been linked to cancer risk; these appear to
primarily alter PR expression levels rather than impact
PR transcriptional activity [9-11]. Two PR protein iso-
forms, PR-A and PR-B, are co-expressed in breast tissues.
PR-B is the full-length receptor, containing 164 amino
acids at the N-terminus (termed the B-upstream segment
or BUS) that are absent from PR-A. Both isoforms are
heavily post-translationally modified (phosphorylation,
ubiquitination, acetylation). PR N-termini contain key
regulatory phosphorylation sites (for example, Ser294) as
well as a SUMOylation site (Lys388) investigated herein.
PR-B, but not PR-A, is phosphorylated on Ser294 in cell
culture and in vivo [12]. Upon ligand binding, both PR
isoforms are rapidly (15 minutes) SUMOylated at Lys388
[13]. SUMOylation occurs via the covalent attachment of
a small ubiquitin-like modifier (SUMO) peptide (approxi-
mately 11.5 kD) to lysine residues of substrate molecules,
primarily at consensus SUMOylation motifs (IKxE)
through an ATP-dependent enzymatic (three step)
mechanism, similar to that of ubiquitination [14].
Substrate SUMOylation often alters protein-protein
interactions, subcellular location, protein stability (that is,
it can oppose ubiquitination), and/or enzyme or tran-
scriptional activities [15].
Recently, Daniel et al. discovered that PR-B phosphory-
lation at Ser294, in response to activated mitogen activated
protein kinases (MAPKs) or cell cycle-dependent protein
kinase-two (CDK2), prevents progestin-induced rapid
SUMOylation at Lys388 [13,16]. Additionally, Ser294
phosphorylation-induced antagonism of PR SUMOylation
derepressed (activated) PR transcriptional activity at
selected breast cancer-associated gene promoters, namely
HBEGF [13], STC1 and IRS1 [16]; phospho-PR-dependent
upregulation of the breast cancer-associated drivers, STC1
and IRS, occurred in the absence of progestins [16]. Pro-
moter structure (that is, the number of hormone response
elements) is a key determinant of reporter-gene promoter
recognition by SUMOylated glucocorticoid receptors
(GRs) [17], while much less is known about how steroid
receptor (SR) SUMOylation alters the regulation of endo-
genous genes (that is, in chromatin). To date, only a few
endogenous genes have been shown to be sensitive to PR
SUMOylation [13,16]. We propose that PR acts as a sensor
for activated mitogenic protein kinases (that is, MAPKs
and CDK2) frequently elevated in human breast cancer;
under the influence of elevated Ser294 phosphorylation,
genes that are sensitive to (that is, normally repressed by)
PR SUMOylation may instead cooperate to drive breast
cancer cell proliferation and pro-survival signaling. A
phospho-PR (SUMO-deficient) gene signature may iden-
tify a subset of human breast cancer patients likely to
respond to endocrine therapies that contain a selective
antiprogestin.
We addressed mechanisms of PR promoter selectivity
related to dynamic post-translational events (that is, PR
Ser294 phosphorylation coupled to Lys388 deSUMOyla-
tion). We employed whole genome expression analysis to
identify genes that are differentially regulated by wild-
type (WT) and SUMO-deficient (K388R) PR-B and
explored the mechanisms responsible for altered PR pro-
moter selectivity. Our findings implicate SUMO-deficient
phospho-PR-B in the selective regulation of genes that
are important for breast cancer cell proliferation and are
pro-survival, and suggest that phosphorylated and deSU-
MOylated PRs may be important drivers of the ERBB2+
phenotype associated with rapid (luminal) breast cancer
tumor progression.
Materials and methods
Progesterone receptor expression in human breast tumor
samples
De-identified human breast tumor samples were
obtained from the University of Minnesota Tissue Pro-
curement Facility’s Biological Materials Procurement
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Network (BioNet) for protein and mRNA analysis. Fro-
zen tissue samples were derived from patients diagnosed
with either ductal carcinoma, infiltrating ductal carci-
noma, lobular carcinoma, or metastatic carcinoma. Spe-
cimens were analyzed by the University of Minnesota
clinical pathology department and scored for ER and PR
expression using standard clinical histological methods.
Tumor samples were harvested individually for protein
or mRNA using standard methods (frozen tissue grind-
ing, radioimmunoprecipitation assay (RIPA) buffer, tri-
reagent), and total PR, phospho-Ser294 PR and ERK1/2
protein expression levels were measured by western
blotting (described below). All specimens were obtained
from patients with informed consent and approval from
University of Minnesota Institutional Review Board
(IRB).
Cell culture, expression vectors and western blotting
T47Dco parental cell lines were characterized previously
[18]. T47D cells stably expressing PR were created by
molecular cloning of cDNAs encoding either WT,
K388R, S294A, or K388R/S294A PR into a pIRES-neo3
expression vector (Clontech, Mountain View, CA, USA,
catalog #631621), followed by transfection of vectors
into T47D-Y cells [19] using FuGENE HD (Roche,
Indianapolis, IN, USA, catalog #04709713001). Single-
cell clones were expanded under high G418 selection
(500 ug/ml) and maintained in low G418 selection (200
ug/ml) (EMD Chemicals, Billerica, MA, USA, catalog
#345810). These cells were maintained in complete
minimal essential medium (cMEM) supplemented with
5% fetal bovine serum (FBS), 1% non-essential amino
acids (NEAA), 1% penicillin/streptomycin, 6 ng/ml insu-
lin (CellGro, Manassas, VA, USA, catalog #10-010-CV).
T47D cells expressing inducible PR were described pre-
viously [20]. Inducible PR expression was achieved by
adding AP21967 (10-9 M, Ariad Pharmaceuticals, Cam-
bridge, MA, USA) to cell culture medium for a mini-
mum treatment time of two days. MCF-7 cell lines
expressing PR were created by transfection of pIRES-
neo3 vectors containing cDNA inserts encoding either
WT or KR PR into cells using FuGENE HD. Single-cell
clones were expanded under high G418 selection and
maintained in low G418 selection. MCF-7 cells were
maintained in (D)MEM (CellGro, catalog #10-013-CV)
supplemented with 5% FBS, 1% penicillin/streptomycin.
BT-474 cells (ATCC, Manassas, VA, USA) were main-
tained in Roswell Park Memorial Institute (RPMI) 1640
medium (Gibco, Grand Island, NY, USA, catalog
#11875) supplemented with 10% FBS, 1% penicillin/
streptomycin. SDS-PAGE was performed using 8% gels
and western blotting analysis was performed as pre-
viously described [13]. For antibody information, see
Additional file 1.
Gene expression profiling
T47D cells stably expressing pIRES-neo3 empty vector,
WT or KR PR were serum starved in modified improved
MEM (IMEM (Gibco, catalog #A10488) for one day,
treated with R5020 (10-8 M) or vehicle control for six
hours before RNA extraction using a RNeasy kit (QIA-
gen, Germantown, MD, USA, catalog #74104). Six hours
of progestin treatment allowed for substantial PR-depen-
dent gene expression as compared to prior studies
[21,22]. DNase I treated (QIAgen, catalog #79254) RNA
samples from duplicate experiments were prepared for
expression analysis using the Illumina HT-12v4 bead
chip platform (San Diego, CA, USA) according to the
manufacture’s protocols. Data were analyzed within R
software [23] using the Bioconductor [24] package called
lumi where raw intensities were log2 transformed and
quantile normalized. Differentially expressed genes were
analyzed using the limma package, where empirical
Bayes was used to better estimate the variance of the
genes. Gene expression data presented contain log2 nor-
malized intensities and biological comparisons presented
(for example, R5020/vehicle) contain log2 fold change
with the Benjamini and Hochberg (BH) adjusted P value
[25]. To generate the heat map in Figure 1C, unsuper-
vised hierarchical clustering of genes was carried out
using the heatmap.2 function in the R package gplots.
Clustering was performed using Euclidean distance and
complete linkage. Rows were scaled to have mean zero
and standard deviation equal to one.
Gene expression profiles in T47D cells expressing
inducible PR were measured using the Affymetrix micro-
array platform (Santa Clara, CA, USA). PR expression
was induced with AP21967 (10-9 M) for two days, cells
were serum starved in modified IMEM for one day and
treated with R5020 (10-8 M) or vehicle control for six
hours before RNA extraction using an RNeasy kit. DNase
I treated samples were prepared for expression analysis
using the Affymetrix U133A 2.0 microarrays according to
the manufacture’s protocols. Raw Affymetrix CEL files
were processed and normalized within R using the Bio-
conductor [24] packages, affy and affyQCReport. Data
were normalized using the Robust Multi-array Average
[26] algorithm within the affy package. Wilcoxon-signed
rank tests as part of the MAS 5.0 algorithm (also
included in the affy package) were used to determine pre-
sence/absence calls for all probe sets [27]. Normalized
expression levels for selected pairs of conditions were
computed as log2 ratios. All gene expression data is avail-
able in the NCBI Gene Expression Omnibus (GEO) data-
base (accession number: GSE34149).
RT-qPCR
For reverse transcription quantitative polymerase chain
reaction (RT-qPCR) assays, 5 × 105 cells/well were plated
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Figure 1 Gene expression profiling of T47D cells stably expressing WT or SUMO-deficient PR, treated with or without R5020 for six
hours. (A) Western blot showing total and phospho-Ser294 PR proteins (total ERK1/2 served as a loading control) in 12 human breast tumors.
(B) T47D cells stably expressing either wild-type PR-B (WT), SUMO-deficient mutant K388R PR-B (KR), or empty vector (null) controls were treated
without or with R5020 prior to western blotting for PR-B. (C) Heat map showing normalized expression values for differentially expressed
transcripts (fold change > 8.0 in at least one sample, BH adjusted P < 0.001). Biological duplicates are shown for each treatment group and
notable gene expression categories (numbered 1-4 on right side) are described (see Results). (D) Venn diagrams showing up- or down-regulated
PR target genes following progestin treatment (log2 fold change > 0.6, BH adjusted P < 0.01; common fold change > 1.5). (E) Venn diagrams (as
in part D) depicting the number of ligand-independent (LI) PR target genes up- or down-regulated relative to PR-null cells. (F) Relative mRNA
expression (as determined by RT-qPCR) of selected PR target genes in T47D cells stably expressing vector control (PR-null), WT or KR PR and
treated without or with R5020 for six hours; genes chosen from ligand-dependent (LD) or LI Venn categories are indicated (note matching color
labels). Data are represented as mean of n = 3 +/- SD. [See also Additional file 5. BH, Benjamini and Hochberg; n, number; PR, progesterone
receptor; SD, standard deviation; SUMO, small ubiquitin-like modifier.
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in six-well dishes, serum starved in modified IMEM for
one day before treatments (see individual figures). RNA
was extracted using TriPure reagent (Roche, catalog
#11667157001) and cDNA was created using the Tran-
scriptor cDNA first-strand cDNA synthesis kit (Roche,
catalog #04897030001). Relative expression levels were
determined by qPCR assays performed on a Roche Light-
Cycler II using SYBR green master-mix (Roche, catalog
#04887352001). Target gene quantification levels were
normalized to the expression of standard housekeeper
genes: TBP, ACTB, and/or GAPDH. For cells expressing
inducible PR, the protocol was the same as above, except
prior to ligand treatments, the cells were induced with
AP21967 (10-9 M) for two days.
For RT-qPCR assays involving epidermal growth factor
(EGF) treatment, cells were plated at 5 × 105 cells/well in
six-well dishes and serum starved for two days in modified
IMEM. Cells were pre-treated with 100 ng/ml EGF
(Sigma, St. Louis, MO, USA, catalog #E9644) before treat-
ment with R5020 (10-8 M).
For experiments using MEK inhibitors, BT-474 cells
were plated in six-well dishes at 5 × 105 cells/well. One
day later, the cells were washed and serum starved in
modified IMEM for one day. These cells were pre-treated
with the MEK inhibitor U0126 (5 uM, EMD Chemicals,
catalog #662005) for 30 minutes. R5020 (10-8 M) and/or
RU486 (10-7 M) was then added to the cell culture wells
for six hours before RNA/protein isolation and RT-qPCR/
western blotting was performed, as described above. PCR
primer sets used in this study are provided in Additional
file 1.
Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA) was used to compare
two distinct gene lists: those upregulated by progestin in
T47D cells expressing WT PR compared to genes upregu-
lated by progestin in cells expressing SUMO-deficient PR
[See Additional file 2, +R5020/-R5020 log2 fold change >
1.0, BH adjusted P < 0.01]. These gene lists were uploaded
into the IPA software where a core analysis was completed
to determine the association of each gene with various
biological functions or network pathways. IPA comparison
analyses were used to reveal whether or not cells expres-
sing WT or KR PR upregulated functionally distinct path-
ways. Analyses were scored based on significance (the BH
adjusted P value, corrected for multiple hypothesis testing)
and the threshold for a gene list to be significantly
involved in a particular biological function was P < 0.05
(or -log10(BH adjusted P value) > 1.30).
Identification of PR expression metagenes
Metagene analysis was conducted using gene expression
microarray data from cell lines constitutively expressing
empty vector, WT PR, or K388R PR, and treated with
either vehicle or R5020. A strategy of identifying meta-
genes within each sample was employed using non-nega-
tive matrix factorization [28]. This strategy facilitated
identification of metagenes and application to other data-
sets. To limit the study to genes under high variance and
to limit the number of probes used in calculating the
metagene fit, probes were considered for metagene analy-
sis based on the interquartile range (IQR) of the probe
being in the upper 80th percentile. The optimum rank of
the data was calculated as eight; therefore, eight meta-
genes are present in the data. Three of these metagenes
were either highly expressed in all samples, or expressed
in no samples, indicating that they are likely metagenes
for housekeeping or continually expressed genes. The
remaining five metagenes corresponded to the empty
vector PR-null samples (with no distinction between the
-R5020 and +R5020 treatment), and the pairwise combi-
nation of WT or KR PR, with or without R5020. Thus,
these analyses identified metagenes from biologically
relevant subtypes of cells.
The Loi et al. human breast tumor dataset [29] contains
gene expression data for both tamoxifen treated and
untreated samples across several datasets. These data were
aggregated together and are available through the gene
expression omnibus (GEO) (accession number GSE6532).
The dataset [29] was loaded into Red-R [30] for proces-
sing. The basis matrix for the metagene analysis was
reshaped to aggregate across the gene symbols and average
the metagene values across each probe of the gene (aver-
age value). The same manipulation was performed on the
expression data. Non-matching genes (those that were
present in the metagene data but not in the clinical
expression data or vice versa) were removed from analysis.
The reshaped data were supplied to the nonnegative
matrix factorization (NMF) package function (fcnnls) for
scoring (as was done to generate the initial metagene fit
on the T47D cell line data). As the Loi et al. data are sup-
plied as z-scores, the data were un-logged and used in the
fcnnls algorithm (as they contain negative numbers in
their normal form). Samples were taken to express a meta-
gene if they showed a non-zero value in the fitted coeffi-
cient matrix (scoring matrix).
Identification of novel PR-target genes and comparison
analysis of gene expression platforms
Ligand-dependent and -independent PR-target gene lists
from two previously published studies [21,22] were com-
bined (duplicates were removed). Genes identified
herein were upregulated (> 1.5 fold BH adjusted P <
0.01) as measured using either platform (Illumina and
Affymetrix were combined) and duplicates were
removed before Venn diagram comparison to previously
known upregulated genes using the bioinformatics tool,
VENNY [31].
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Gene set enrichment analysis (GSEA) software [32,33]
was employed to compare genes up- or down-regulated
in cells stably expressing WT or KR PR to cells expres-
sing inducible iWT or iKR PR [See Additional file 3].
Using the Affymetrix expression data, four gene sets
were created: genes up- or down-regulated > 2.0 fold by
iWT with R5020, and genes up- or down-regulated >
2.0 fold by iKR with R5020. Similarly, two GSEA-for-
matted datasets were created from the Illumina expres-
sion data: the first dataset compares the two phenotypes
(WT +R5020 versus WT -R5020), and the second com-
pares the two phenotypes (KR +R5020 versus KR
-R5020). GSEA was performed using those Illumina
datasets and queried for enrichment of the Affymetrix
gene sets. GSEA was executed using the default settings,
except the permutation type was set to Gene_set with
1,000 permutations, and the metric for ranking genes
was set to Diff_of_Classes because our dataset contained
log-scale data.
Chromatin immnunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed according to the ChIP-IT Express instruction
manual (Active Motif, Carlsbad, CA, USA, catalog #
53008). Cells were plated at 15 × 106 cells per 15 cm cul-
ture dish in cMEM for two days, then serum starved in
modified IMEM for two days. Cells were treated with
R5020 (10-8 M) or vehicle for one or four hours. For
T47D cells expressing inducible PR, AP21967 (10-9 M)
was added during the starvation step. Chromatin was
sheared using a Bioruptor sonicator (Diagenode, Denville,
NJ, USA, model UCB-200), for 30 minutes (30 seconds
on/off). Immunoprecipitations were prepared with 60 ul
of sheared chromatin, 2 ug antibody and immunoprecipi-
tated overnight. Using the purified ChIP and input DNA,
relative recruitment was determined by qPCR in tripli-
cate. Assays were performed on a Roche LightCycler II
using SYBR green master-mix. Target locus quantifica-
tion was normalized as a percentage of the input DNA
quantification.
To assay H3K4me2 levels, nucleosomes were isolated
using micrococcal nuclease (MNase). In 15 cm dishes,
12 × 106 cells were plated in cMEM, serum starved in
modified IMEM and induced with AP21967 (10-9 M)
treatment for two days. One day later, cells were treated
with R5020 (10-8 M) for four hours and chromatin was
harvested and immunoprecipitated as previously described
[34].
Cell proliferation and apoptosis assays
Cell proliferation was measured using MTT assays (3-[4,5-
dimethylthiazol-2-yl]- 2,5-diphenyltetrazolium bromide,
Sigma catalog #M2128). In 24-well plates, 1 × 104 cells/
well were plated in cMEM (inducible PR expression was
induced with AP21967 (10-9 M) for two days), cells were
washed and steroid starved in modified IMEM supplemen-
ted with 5% dextran-coated charcoal-treated (DCC) FBS
for one day before the addition of R5020 (10-8 M). At days
0, 2, 4, and 6, cell proliferation was determined by adding
60 ul MTT (5 mg/ml) to each 0.5 ml cell culture well for
three hours, medium was carefully removed and solubili-
zation solution (90% v/v dimethyl sulfoxide (DMSO)/PBS)
was added to lyse the cells. Lysate absorbance (650 and
570 nm) was measured using a plate reader. The 650 nm
measurements were subtracted from 570 nm measure-
ments and sample means were normalized to day zero.
Poly (ADP)-ribose polymerase 1 (PARP) cleavage
assays were used to measure the level of apoptosis in cell
cultures after treatment with cytotoxic concentrations of
doxorubicin. T47D cells expressing inducible PR were
plated in 10 cm dishes (2 × 106 cells/dish) in cMEM and
induced with AP21967 (10-9 M). Cells were washed,
induced, and serum starved for four days. Cells were then
treated with R5020 (10-8 M) for six hours before adding
doxorubicin (8 uM) to dishes for 24 hours. Protein was
harvested using standard RIPA lysis buffer, subjected to
SDS-PAGE and western blotting using cleaved-PARP
and PR antibodies. Beta-actin western blotting was per-
formed for sample loading controls.
Cell viability after treatment with cytotoxic doxorubicin
was determined by measuring the concentration of ATP,
which is directly proportional to viable cell number [35],
using Cell-Titer-Glo bioluminescence assays (Promega,
Madison, WI, USA, catalog #G7571). T47D cells expres-
sing WT or KR PR were plated in 24-well dishes (1 × 104
cells/well) containing cMEM. Cells were washed and ster-
oid starved in modified IMEM supplemented with 5%
DCC FBS for one day. Cells were treated with R5020 (10-8
M) for six hours before doxorubicin (6 uM) was added to
the wells. After four days, cell viability was determined by
adding Cell-Titer-Glo substrate and luminescence was
measured using a plate reader. Sample means were nor-
malized to day zero (n = 6, -/+ standard deviation (SD)).
Oncomine data analysis
The relative expression of individual PR target genes in
human breast tumor samples was determined by searching
the Oncomine database (version 4.4, October 2011 data
release, [36]). Individual PR target genes (for example,
RGS2) were queried in The Cancer Genome Atlas
(TCGA) Breast 2 dataset. Oncomine output data was
sorted to isolate ‘cancer versus normal’ associations and
reported (Figure 2A) as the copy number unit expression
values for blood, normal breast and breast carcinoma sam-
ples using box-and-whiskers plots (dots: maximum/mini-
mum, whiskers: 90/10 percentiles, box: 75/25 percentiles,
line: median of all samples). For each analysis, specific
breast carcinomas specified for each gene are: Invasive
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Figure 2 Phosphorylation of PR Ser294 drives SUMO-deficient PR gene expression and promoter selectivity in MCF-7 and T47D cells.
(A) Relative expression level (copy number) of PR target genes in breast cancer patient cohorts. (B) Relative gene expression levels of selected
PR target genes in MCF-7 cells stably expressing either empty vector (PR-null), WT or SUMO-deficient K388R PRs. Cells were co-treated with
progestin R5020 and/or antiprogestin RU486 for six hours and mRNA levels were measured using RT-qPCR (see Materials and methods). (C)
Relative gene expression levels of the same PR target genes (as in parts A-B) were measured using RT-qPCR in five vector-matched T47D cell
lines stably expressing PRs: empty vector (null), wild-type (WT) PR, K388R mutant (KR) PR, S294A mutant (SA) PR, and K388R and S294A double
mutant (KRSA) PR. Cells were treated with R5020 for six hours. (D) T47D cells expressing WT PR were treated cells with epidermal growth factor
(EGF) for two days and treated with R5020 for 3, 24, or 48 hours. Relative MAP1A and RGS2 mRNA levels were measured using RT-qPCR. (E)
Parental T47Dco cells were pretreated with EGF for 20 minutes prior to 24 hours of R5020 treatment. Relative RGS2 mRNA levels were measured
by RT-qPCR. Data are represented as mean of n = 3 +/- SD and significance calculated using Student’s t-test. n, number; PR, progesterone
receptor; SD, standard deviation; SUMO, small ubiquitin-like modifier; WT, wild type.
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Lobular Breast Carcinoma (MSX2), Invasive Ductal and
Lobular Carcinoma (RGS2), Intraductal Cribriform Breast
Adenocarcinoma (MAP1A), and Mucinous Breast Carci-
noma (PDK4).
Multiple breast cancer ‘concepts’, as described in the
Oncomine database, were associated with the ligand
dependent (LD) KR > WT gene signature [See Additional
file 4]. According to Oncomine, concepts are derived
from gene expression microarrays or gene-copy-number
datasets derived from tumor cohorts or cancer cell line
experiments. Specifically, concepts are a list of genes
from various published datasets that are defined by some
criteria (for example, top 5% of genes expressed in
ERBB2-positive breast tumors). The LD gene signature
was created by normalizing the gene expression values in
the +R5020 treatment group to the -R5020 treatment
group, then comparing those normalized fold change
values between the KR and WT PR expressing cell lines.
This analysis identified 151 LD genes upregulated > 1.5
fold in cells expressing SUMO-deficient PR versus WT
PR expressing cells. The ligand-independent (LI) gene
signature was created by normalizing the gene expression
values in -R5020 treatment group in WT or KR expres-
sing cells to the -R5020 treatment group in the PR-null
expressing cells, then comparing those normalized fold
change values between the KR and WT expressing cell
lines. This analysis identified 92 LI genes upregulated >
1.5 fold in cells expressing SUMO-deficient PR versus
WT PR expressing cells. These PR gene signatures were
uploaded into Oncomine Research Premium Edition soft-
ware (Compendia Bioscience, Ann Arbor, MI, USA [37])
and the database was searched for associated concepts.
Results
PR SUMOylation alters promoter selection in T47D breast
cancer cells
For unknown reasons, there is little overlap between PR-
regulated genes in normal, relative to neoplastic, breast
tissues [38]. One mechanism for the apparent divergence
of PR functions may relate to early events in breast can-
cer development, such as altered signal transduction.
Based in part on our prior studies [13,16,39], we predict
that the balance between SUMOylated and phosphory-
lated (that is, deSUMOylated) PRs is frequently altered in
breast cancer, resulting in changes in PR promoter selec-
tivity and altered patterns of gene expression. In a screen
of ten breast tumors clinically defined as PR+, we
detected a wide range of total PR mRNA (not shown)
and protein expression (Figure 1A). Of the seven (out of
10) breast tumors that were confirmed to be PR+ by both
RT-qPCR and western blotting, at least five samples
(lanes one, three, six, eight, and nine) also clearly con-
tained some level of phospho-Ser294 PR-B (Figure 1A).
Remarkably, two of ten tumors (lanes one and three)
contained abundant phospho-Ser294 PR-B. Notably, PR-
B, but not PR-A, Ser294 is rapidly phosphorylated in
response to either progestins or peptide growth factors
that input to proline-directed protein kinases, primarily
within the MAPK and CDK families [12]. Consistent
with this finding, EGF blocked progestin-induced PR-B,
but not PR-A SUMOylation [13].
The broad range of PR expression in clinical specimens
(Figure 1A and [40]) suggests that PR-dependent gene
expression may provide a more accurate marker of PR
contribution to breast cancer phenotypes. To address the
unique actions of phosphorylated and SUMO-deficient
PR-B, we measured the transcriptional profiles of breast
cancer cells stably expressing either wild-type (capable of
SUMOylation) or SUMO-deficient (K388R mutant/phos-
pho mimic) PR-B molecules using whole genome expres-
sion profiling. We first engineered multiple clones of
vector-matched PR-null T47D breast cancer cells expres-
sing either WT PR-B or mutant K388R (KR) PR-B that is
unable to undergo SUMO modification at Lys388; this
SUMO-deficient receptor is a functional mimic for PR-B
that is persistently phosphorylated on Ser294 [13,41].
Phospho-Ser294 and S294D receptors are hyperactive
transcription factors that undergo rapid ligand-depen-
dent (ubiquitin-mediated) downregulation relative to WT
PRs [39]. Cells expressing either WT or KR PR-B were
then treated with the synthetic progestin, R5020 (10-8
M), for six hours (Figure 1B). Upon ligand-binding, PR is
globally phosphorylated at multiple sites, as indicated by
a slight gel upshift [42]. Consistent with our previous
reports [13,16] hyperactivated KR PR undergoes slightly
more rapid ligand-induced (ubiquitin proteasome-depen-
dent) downregulation (apparent at six hours) relative to
WT PR [41]. Using these experimental conditions, global
gene expression profiles were simultaneously measured
using Illumina HT-12v4 whole genome gene expression
bead arrays (Figure 1C). Top regulated genes were orga-
nized by heat maps showing up- or down-regulated
genes (fold change > 8.0 in at least one sample, BH
adjusted P < 0.001, Figure 1C). Upon progestin treat-
ment, these cells displayed diverse expression patterns;
multiple PR-regulated gene sets became readily apparent
(Figure 1C; compare groups of PR-regulated genes upre-
gulated (1a) or downregulated (1b) by LD PRs relative to
untreated controls, genes upregulated (2a) or downregu-
lated (2b) by LI PRs relative to PR-null controls, and LD
genes upregulated primarily in KR relative to WT (3) or
WT relative to KR (4) expressing cell lines).
We identified genes that were upregulated > 1.5 fold
by PR in a LD orLI manner and discovered gene expres-
sion overlap between cells expressing either KR or WT
receptors, as well as subsets of uniquely regulated genes
(Figure 1D-E, Additional file 5). We next validated the
expression profiles for numerous PR target genes from
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these classes using RT-qPCR (Figure 1F). Notably, RGS2
expression (primarily upregulated by the KR receptor) is
over-expressed in the basal/myoepithelial compartment
and substantially elevated in a majority of breast tumors
[43]. In contrast, BCL2L11 (BIM) is a pro-apoptotic
mediator involved in ERBB/MAPK-dependent luminal
cell clearing [44] whose expression is primarily upregu-
lated by WT but not KR receptors. As these examples
suggest, our gene array robustly identified diverse classes
of PR target genes, and contains gene expression profiles
indicative of mechanisms of PR-mediated cellular prolif-
eration and survival.
These results essentially repeated in T47D cells engi-
neered to express either WT or KR PR from an induci-
ble vector system [See Additional file 3]. In this model,
inducible expression of PRs (iWT or iKR) is solely
dependent on the presence of a small molecule dimeri-
zer, AP21967, added to the cell culture medium; equal
levels of either iWT or iKR were induced upon treat-
ment with AP21967 and these receptors were equally
phosphorylated on Ser294 in response to progestin [See
Additional file 2]. Cells were treated with AP21967 (10-9
M) and R5020 (10-8 M) and assayed for changes in gene
expression using the Affymetrix U133A 2.0 microarray
platform. Remarkably, PR-dependent gene expression
profiles obtained from T47D cells stably expressing PR
(assayed using the Illumina platform) were significantly
similar to gene array data obtained from the same par-
ental cells (T47D) inducibly expressing PR (assayed via
the Affymetrix platform; see Additional file 2). Together,
our arrays identified a greater number of PR regulated
genes (> 1.5 fold, BH adjusted P < 0.01) than previous
reports [21,22]; microarray platforms now contain thou-
sands more ‘reporters’ relative to earlier technologies.
Notably, we identified 70% of the previously known PR
target genes but also revealed hundreds of novel PR tar-
get genes [See Additional file 6].
Phosphorylation of PR Ser294 drives SUMO-deficient PR
gene expression
To investigate mechanisms of regulation of ‘SUMO-sen-
sitive’ PR-target genes, we selected four genes (MSX2,
RGS2, MAP1A and PDK4) from our microarray analysis
for further study. These specific genes were dramatically
upregulated in cells expressing KR, but not WT recep-
tors (Figure 1D, yellow category). A query of the Onco-
mine database [36] demonstrated that all four genes are
amplified in breast carcinomas relative to normal breast
tissue and blood (Figure 2A). To validate SUMO-depen-
dent changes in PR target gene expression in an addi-
tional breast cancer model, we stably introduced vector
control, WT or KR receptors into MCF-7 cells expres-
sing low levels of endogenous PR (in the absence of
estrogen). These cells were treated with vehicle control
(ethanol) or R5020 (10-8 M) in the absence or presence
of the PR antagonist, RU486 (10-7 M) for six hours (Fig-
ure 2B). Notably, progestin-induced gene expression
profiles in MCF-7 cells were nearly identical to those
obtained in our T47D cell models (MSX2, RGS2,
MAP1A, and PDK4). Additionally, their R5020-induced
mRNA expression was completely abolished by addition
of RU486, indicating that regulation of these genes is
indeed entirely PR-dependent.
We showed previously that SUMO-deficient KR
receptors closely mimic phospho-Ser294 (WT) PR spe-
cies [13]. To demonstrate the phosphorylation-depen-
dence of PR regulation on the same set of genes (MSX2,
RGS2, MAP1A, and PDK4), we employed PR-null T47D
cells or T47D cells stably expressing WT, KR, or phos-
pho-mutant S294A (SA) PR-B [41]. Mutation of PR
Ser294 results in a heavily SUMOylated receptor that is
transcriptionally repressive, as measured by luciferase
reporter assays [13]. Consistent with this finding, pro-
gestin-induced upregulation of endogenous PR target
genes was blocked in cells expressing S294A PR relative
to cells expressing SUMO-deficient KR PR (Figure 2C).
Furthermore, progestin-induced gene expression was
rescued (that is, comparable to that induced in R5020-
treated KR cells) in cells expressing the PR double
mutant (KRSA), containing point mutations at both
Ser294 and Lys388, suggesting that PR deSUMOylation
is the dominant event required for LD upregulation
(derepression) of these phosphorylation-dependent PR
target genes.
Treatment of breast cancer cells with EGF induces
robust PR Ser294 phosphorylation and deSUMOylation
[13]. We therefore pre-treated T47D cells stably expres-
sing WT PR with EGF (100 ng/ml) followed by vehicle
control or R5020 (10-8 M). Both MAP1A and RGS2
were insensitive to EGF alone over a two-day time
course (Figure 2D). However, EGF pre-treatment signifi-
cantly augmented progestin stimulated mRNA expres-
sion of both genes (Figure 2D). We observed similar
results for RGS2, but not MAP1A expression in parental
(expressing both endogenous PR-A and PR-B isoforms)
T47Dco cells treated for six hours (Figure 2E). Perhaps
not surprisingly, multiple factors (that is, strength and
duration of PR phosphorylation, transcriptional activity,
and protein levels) likely influence the kinetics of PR-
regulated MAP1A expression in cells stimulated broadly
with growth factors. Notably, in T47D cells stably
expressing WT PR-B, MAP1A mRNA expression was
synergistically upregulated following just three hour of
treatment with progestin plus heregulin-b1; progestin-
alone approached this by 24 hours (data not shown).
Taken together, our data suggest that PR dynamically
regulates multiple endogenous genes according to its
phosphorylation and SUMOylation status; growth
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factors favor phospho-PR that act as derepressed tran-
scription factors.
PR SUMO modification provides a mechanism for
promoter selection
Our gene array analyses indicated that SUMO modifica-
tion of PR alters the magnitude of transcriptional
response on selected promoters, while the regulation of
other PR target genes is completely insensitive to PR
SUMOylation (Figure 1). To investigate mechanisms of
PR promoter selection, we examined the recruitment of
PR and selected coregulators to the chromatin of differ-
entially regulated PR target genes. We initially focused
on MSX2. Similar to PR-B, this homeobox transcription
factor is essential for mammary gland development and
transgenic expression of MSX2 causes ductal hyperplasia
in mice [45,46]. Functional studies indicate that MSX2
induces cyclin D1 and E1 expression [47], is involved in
RAS-mediated cellular transformation [48] and drives
epithelial-to-mesenchymal transition through downregu-
lation of epithelial markers [49]. Lanigan et al. [50]
showed that MSX2 expression is significantly elevated in
both luminal B and HER2-enriched molecular subtypes
of breast cancer, despite being associated with good
prognosis (that is, similar to ER and PR). We identified
multiple consensus progesterone response element
(PRE) sequences up- and downstream of the MSX2
transcriptional start site using MatInspector software
[51]. In particular, one PRE aligned with a region of
known PR recruitment, based on the PR cistrome
(derived from unpublished ChIP-chip experiments
kindly provided by Myles Brown, Harvard). Recall that
MSX2 is transcriptionally upregulated in response to
progestin treatment of T47D or MCF-7 cells stably or
inducibly (T47D) expressing SUMO-deficient PR, but
not WT receptors (Figure 2B-C, Additional file 3). To
investigate direct recruitment of PR to the PRE enhan-
cer region of MSX2 (Figure 3A), we treated cells consti-
tutively (or inducibly) expressing either WT or KR PR
with R5020 (10-8 M), and performed ChIP assays. Fol-
lowing progestin treatment, both WT and KR PR were
readily detected at the PRE enhancer region (Figure 3B
left), although we detected no transcriptional activity
(mRNA levels as measured by RT-qPCR) in progestin-
treated cells expressing WT PR (Figure 2B-C, Additional
file 3). Notably, significantly more SUMO-deficient KR
PR was recruited to the MSX2 enhancer locus relative
to that of WT PR. This finding repeated in cells expres-
sing inducible PR (Figure 3B right) as well as at PRE-
containing enhancers of multiple other genes upregu-
lated by SUMO-deficient PR [See Additional file 7]. We
then investigated the recruitment of a common PR tran-
scriptional coactivator, cAMP-response element-binding
protein (CREB)-binding protein (CBP) to the MSX2
enhancer locus. CBP interacts with multiple nuclear
receptors, functions as a transcriptional scaffold, and has
histone acetyltransferase (HAT) activity [52-54]. Using
ChIP assays, we determined that upon progestin treat-
ment, CBP recruitment to the MSX2 locus is signifi-
cantly elevated in cells expressing SUMO-deficient KR
PR, but not WT PR (Figure 3C). Consistent with the
increased presence of this coactivator associated with
KR PR, we observed increased recruitment of total and
functionally active phospho-Ser5 RNA polymerase II to
the MSX2 proximal promoter region in progestin-trea-
ted cells expressing iKR PR relative to cells expressing
iWT PR [See Additional file 8]. These data may explain
why, although WT PR is clearly recruited to this region
in the presence of progestin (Figure 3B), significant
mRNA expression does not occur (Figure 2B-C, Addi-
tional file 3). We previously reported constitutive asso-
ciation of deSUMOylated PRs and steroid receptor
coactivator 1 (SRC1) at endogenous gene loci [16].
Histone tail modifications (methylation, acetylation,
phosphorylation, and so on) are epigenetic modifications
known to significantly impact chromatin dynamics and
thereby affect changes in gene expression (reviewed in
[55]). Generally, histone H3 Lys4 dimethylation
(H3K4me2) is an epigenetic mark associated with tran-
scriptional activation [56,57]. H3K4me2 marks areas of
transcription factor-facilitated paired nucleosome posi-
tioning, and is an indicator of nearby gene activation [57].
To measure the level of H3K4me2 at the MSX2 enhancer
locus, T47D cells expressing inducible PRs (iWT and iKR)
were treated with R5020 (10-8 M) for four hours and
nucleosomes were isolated after micrococcal nuclease
(MNase) digestion; histone methylation was determined
by ChIP, followed by qPCR (Figure 3D left). H3K4me2
levels were elevated in progestin-treated cells expressing
iKR relative to cells expressing iWT PR. We also measured
the R5020-induced fold change in H3K4me2 surrounding
the MSX2 PRE locus (approximately 500 bp up- and
downstream using overlapping qPCR products) to visua-
lize local histone dimethylation patterns (Figure 3D right).
Progestin-dependent H3K4me2 was enriched in cells
expressing SUMO-deficient iKR PR compared to cells
expressing iWT. Indeed, the higher levels of histone
methylation flanking the PRE sequence are likely a conse-
quence of nucleosome remodeling and spreading that
facilitates recruitment of transcription factor complexes at
this functional enhancer region [57].
These results suggest that one or more histone methyl-
transferases are differentially recruited to the MSX2
enhancer in cells expressing either iWT or iKR PR.
Recently, a chromatin remodeling complex, including the
subunit mixed lineage leukemia 2 (MLL2) methyltransfer-
ase, was implicated in progestin-dependent H3K4 tri-
methylation [58]. Additionally, ER-alpha interacts directly
Knutson et al. Breast Cancer Research 2012, 14:R95
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Figure 3 Promoter selectivity is achieved through increased recruitment of SUMO-deficient KR PR, CBP, MLL2 and histone tail
modification, H3K4me2, to enhancer loci. (A) Schematic showing the MSX2 gene PRE-containing enhancer region located 15,094 bp
upstream from the transcriptional start site. (B) Relative recruitment of PR to the MSX2 enhancer region was measured by ChIP-qPCR assays in
T47D cells expressing constitutive PR null, WT or KR PR after treatment with R5020 for one or four hours. PR recruitment values were normalized
as a percentage of input chromatin DNA values. To control for background non-specific antibody binding, immunoprecipitated chromatin
contained a mixture from all samples with an IgG antibody. Similar ChIP results were obtained in T47D cells expressing inducible PR (right side).
(C) The relative recruitment of CBP to the MSX2 enhancer region was measured as described in part B. (D) Levels of H3K4 dimethylation at the
MSX2 enhancer were measured in the inducible PR expressing cell lines (iWT and iKR). The presence of H3K4me2 was determined at the MSX2
enhancer, up/downstream from the PRE, using overlapping qPCR products that span the region. (E) MLL2 recruitment to the MSX2 enhancer
region was determined in T47D cells expressing both constitutive PR and inducible PR, as described in part B. (F) MAT2A gene expression was
measured by RT-qPCR in T47D cells expressing stable WT or SUMO-deficient KR PR. Additionally, PR and MLL2 recruitment was quantified in
these cells, as measured by standard ChIP-qPCR assay. Data are represented as mean of n = 3 +/- SD and significance calculated using Student’s
t-test. [See also Additional files 7, 5. KR, K388R PR-B mutant]. CBP, CREB-(cAMP-response element-binding protein)-binding protein; ChIP,
chromatin immunoprecipitation; H3K4me2, histone H3 lysine 4 dimethylation; IgG, immunoglobulin G; KR, K388R PR-B mutant; MLL2, mixed
lineage leukemia 2; PR, progesterone receptor; PRE, progesterone receptor response element; SD, standard deviation; SUMO, small ubiquitin-like
modifier; WT, wild type.
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with MLL2 though its LXXLL motifs and MLL2 mediates
estrogen-dependent transcriptional upregulation in MCF-
7 cells [59]. Using both stable and inducible T47D models,
we discovered that MLL2 is significantly recruited to the
MSX2 enhancer in progestin treated cells expressing
SUMO-deficient KR PR, but not WT PR (Figure 3E).
Finally, we measured the relative recruitment of PR to
a PRE-containing enhancer locus near MAT2A, a con-
trol PR-target gene that is insensitive to PR SUMOyla-
tion status (Figure 1D, green category). MAT2A mRNA
expression was equally upregulated in progestin-treated
cells expressing either WT or KR PR (Figure 3F left).
Likewise, progestin-dependent recruitment of PR and
MLL2 to the same PRE-containing region in the
MAT2A enhancer was very similar in cells expressing
either WT or KR PR (Figure 3F center and right).
Taken together, these data suggest that enhancer/pro-
moter structure (in chromatin) functions in combination
with PR SUMOylation to block important interactions
between PR and mediators of early chromatin remodel-
ing (MLL2) as well as major coregulators, including
CBP; higher levels of these factors were specifically asso-
ciated with ‘sensitive’ PRE regions in cells expressing
SUMO-deficient PR. Perhaps SUMO-sensitive enhancer
regions require PR-dependent recruitment of MLL2 in
order to initiate changes in nucleosome positioning at
relatively ‘closed’ regions (that is, with regard to genes
like MSX2). In contrast, pre-existing ‘open’ regions may
be insensitive to PR SUMO modification (that is, with
regard to genes like MAT2A). Additionally, preferential
association of SUMO-deficient PR with other factors
(that is, pioneer-type transcription factors) may contri-
bute to PR promoter selection; KR recruitment to the
MSX2 enhancer region is significantly enhanced relative
to WT receptor in the presence of progestin (Figure
3B). These questions await further detailed global gene
and cistrome analyses (see Discussion).
SUMO-deficient phospho-PR promote increased cell
proliferation and decreased apoptosis
Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
[60]) software contains a large database of genes that
are manually assigned to molecularly defined pathways,
biological functions or disease states, and based on cur-
rent literature. Using this tool, we compared ligand-
dependent upregulated genes (> 2 fold, BH adjusted P <
0.01) in cells stably expressing either WT or KR recep-
tors. Upon progestin treatment, SUMO-deficient PR,
but not WT, significantly upregulated gene sets assigned
to multiple proliferative and pro-survival biological func-
tions [See Additional file 2]. We showed that breast can-
cer cells stably expressing SUMO-deficient PR exhibit
increased growth in soft-agar relative to cells stably
expressing either WT or phosphorylation-deficient
S294A PR [13,16]. We performed MTT proliferation
assays using our inducible models (Figure 4A). The
advantage of this isogenic system is the elimination of
clonal variation in cell growth/death rates and phenoty-
pic drift that can occur in stable cell line models. Cells
were plated at equal density on day zero and treated
with or without the AP21967 compound to induce PR
expression, prior to exposure to either vehicle (ethanol)
or progestin (R5020). Progestin-treated cells expressing
iWT or iKR PRs grew faster than their un-induced or
untreated counterparts. However, by day six of continu-
ous exposure to both AP21967 and R5020, significantly
more cells were present in cultures expressing iKR rela-
tive to those expressing iWT receptors, while all control
groups remained very similar. Western blotting demon-
strated that inducible PR expression was sustained when
AP21967 was added to the cell culture media and that
comparable levels of iWT and iKR PR protein were
expressed (Figure 4B).
MTT assays measure viable (surviving) cells over time
and PRs have been implicated in breast cancer cell pro-
survival [7,61]. Thus, we also measured cleavage of
PARP as an indirect indicator of apoptosis. PARP is tar-
geted for cleavage at Asp214 by activated caspase-3 and
is a sensitive measure of committed apoptotic signaling
[62]. PR expression was induced by AP21967 treatment
and cells were pre-treated with R5020 for six hours to
activate the respective iWT or SUMO-deficient iKR
gene expression programs. Following R5020 pre-treat-
ment, doxorubicin was added to the cell culture med-
ium to induce apoptosis for one day, after which the
cell lysate was harvested and the relative levels of
cleaved PARP were measured by western blotting (Fig-
ure 4C). Notably, doxorubicin-treated cells expressing
SUMO-deficient iKR PR had reduced levels of PARP
cleavage relative to cells expressing iWT PR, especially
in cells pre-treated with R5020 (compare lanes four and
eight). Doxorubicin treatment reduced both WT and KR
PR protein expression (Figure 4C, compare lanes one
and three, or lanes five and seven). However, in multiple
repeat experiments normalized to protein expression
changes, cells expressing iKR PR consistently exhibited
reduced PARP cleavage relative to cells expressing iWT
PR. These findings were validated in T47D cells stably
expressing PRs. PR-null cells and cells stably expressing
either WT or KR PR were plated in complete media,
serum starved and treated with R5020, with or without
doxorubicin (Figure 4D). Again, we observed signifi-
cantly increased cell viability in progestin-treated cells
expressing SUMO-deficient KR PR. Interestingly, when
these cells were challenged with cytotoxic concentra-
tions of doxorubicin, their viability was doubled relative
to cells expressing WT PR (Figure 4D). These data sug-
gest that SUMO-deficient PRs are important mediators
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Figure 4 SUMO-deficient progesterone receptors promote increased cell proliferation and decreased apoptosis. (A) The proliferative
potential of T47D cell lines expressing inducible PR was measured using MTT assays in the presence of progestin (R5020) and inducer, AP21967
(AP) (B) Western blot showing that inducible PR expression is sustained for at least five days following the addition of AP21967 to the cell
culture media, ERK1/2 western blotting was performed as a loading control. (C) Apoptosis occurring in cells expressing inducible PRs was
detected by western blotting for poly (ADP)-ribose polymerase 1 (PARP) cleavage. Cells were treated with progestin and/or doxorubicin before
protein harvest. (D) Proliferation and apoptosis was measured in cells constitutively expressing PR using cell viability luciferase assays, where day
4 luminescence was normalized to day 0. Pooled data are represented as mean of n = 6 +/- SD and significance calculated using Student’s t-
test. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; n, number; PR, progesterone receptor; SD, standard deviation; SUMO, small
ubiquitin-like modifier.
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of increased cell proliferation and pro-survival signaling;
cells expressing modified PRs undergo biological pro-
cesses consistent with their associated gene expression
profiles (Figure 1).
The SUMO-deficient PR gene signature is associated with
ERBB2 positive breast cancers
Human breast cancers often contain high levels of
MAPK, AKT, and/or CDK protein and/or kinase activ-
ities, thus favoring PR derepression [13,16]. To probe
published human breast cancer databases for evidence
of genetic patterns suggestive of phospho-PR-driven
(SUMO-deficient) lesions, we first defined unique PR
gene signatures comprised of genes whose expression
was greater in cells expressing KR relative to cells
expressing WT receptors (expression > 1.5 fold in KR
versus WT, BH adjusted P < 0.01). These genes were
predominantly upregulated in cells expressing KR recep-
tors and/or downregulated only in cells expressing WT
receptors. This analysis was performed for both ligand-
dependent and ligand-independent PR target genes.
Using these criteria, unique 151- and 92-gene signatures
were created and defined as PR-target genes differen-
tially upregulated (compared to WT) by LD and LI KR
receptors, respectively [See Additional file 9].
These gene signatures were then uploaded into the
Oncomine Research Premium Edition (Compendia
Bioscience [37]) and the database was interrogated for
associated concepts (reviewed in [63]). Oncomine con-
cepts are gene lists defined by specific criteria (for
example, top over-expressed genes in a particular tumor
cohort). The LD 151-gene signature was associated with
multiple breast cancer concepts with high significance
(P < 0.0001, FDR < 0.01) [See Additional file 8].
Remarkably, five distinct ERBB2-positive breast cancer
concepts (two from cell lines and three from tumor
cohorts) were independently associated with this LD
PR-gene signature. Thus, genes specifically upregulated
in the presence of progestin in cells expressing SUMO-
deficient PR are among the same genes highly over-
expressed (top 5% to 10%) in ERBB2-positive breast can-
cers (Figure 5A, Additional file 4 Table s1, shaded rows).
Notably, the LI 92-gene signature was also significantly
associated with at least one ERBB2-positive concept
[64]. These data indicate that both LD and LI PR-regu-
lated gene sets are significantly upregulated in protein-
kinase-driven tumors, including those known to be
ERBB2-positive (Figure 5A).
Expression of these related genetic programs (SUMO-
deficient PR and ERBB2 signaling) might represent inde-
pendent means utilized by breast cancer cells to drive
cell proliferation and survival. Indeed, HER2-enriched
breast cancers are frequently SR negative [65,66]. Alter-
natively, these statistically significantly associated
concepts may be functionally linked. Luminal breast
cancers are primarily SR-positive, but approximately 7%
of luminal A and 20% of luminal B tumors are HER2-
enriched [67,68]. We therefore tested the PR- and
MAPK-dependent regulation of selected genes co-asso-
ciated with ERBB2 overexpression (Figure 5A) and
SUMO-sensitivity (above) in HER2-amplified but SR-
positive BT-474 breast cancer cells that contain consti-
tutively activated MAPKs [69]. Antiprogestin treatment
dramatically inhibits BT-474 tumor growth in xenograft
models [70] and significantly blocks BT-474 cell prolif-
eration in MTT assays conducted over six days in vitro;
similar results were observed with the MEK inhibitor,
U0126 (data not shown). We first measured the expres-
sion of PR target genes (CHN2 and RGS2) primarily
regulated by KR (and ERBB2-associated; see Figure 5A
rows) but not WT PR, relative to a control gene not
sensitive to PR SUMOylation (ACOT6; upregulated
equally by WT and SUMO-deficient PR, Figure 1F).
Remarkably, progestin treatment induced elevated PR-B
Ser294 phosphorylation (lane two) and robust upregula-
tion of both CHN2 and RGS2 in BT-474 cells: 17-fold
and 26-fold, respectively (Figure 5B). Recall that RGS2
expression is weakly sensitive to progestin treatment in
T47D cells expressing WT PR (approximately two-fold)
compared to KR PR (approximately 20-fold) (Figure 1F).
ACOT6 expression was also induced by R5020; expres-
sion of all three genes was entirely blocked by antipro-
gestin RU486 (Figure 5B). Note that when CHN2 and
RGS2 mRNA expression is highest (+R5020; compare
lanes one and two), although phospho-Ser294 PR is
readily detected, total PR levels are greatly diminished
and appear undetectable (lane two), presumably due to
LD (proteasome-mediated) downregulation of activated
PR species [41]. Pre-treatment of these cells with the
MEK kinase inhibitor, U0126, blocked R5020-induced
PR Ser294 phosphorylation and partially, but signifi-
cantly, diminished both CHN2 and RGS2 expression
(Figure 5B, lane six). In contrast, the expression of
ACOT6, a control gene unaffected by PR SUMO-status,
was completely insensitive to MEK kinase inhibition.
These data support our hypothesis and demonstrate
that phosphorylation events contribute to both expres-
sion of the SUMO-deficient PR gene signature and PR-
induced proliferation in otherwise unmodified (that is,
containing WT PRs) SR-positive breast cancer cells.
Similar to CHN2 and RGS2 (Figure 5B), we predict that
a significant number of genes upregulated in ERBB2
overexpressing luminal breast cancers are indeed PR-
driven.
The above findings prompted us to test whether PR
gene signatures derived from our cell line models were
predictive of tumor behavior and patient survival in
published human breast tumor cohorts. For example,
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Figure 5 The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts
reduced patient survival. (A) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor
in the patient cohort [64], organized by ERBB2 status. (B) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both
upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both
WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or
antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2
phosphorylation. (C) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D
metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated
ER-positive tumors from the Loi et al. dataset [29]. (D) Survival curves as in part C for patients whose tumors expressed the combined T47D
metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files 4 and 9]. ER, estrogen
receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
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the Loi et al. dataset [29] represents one of the largest
collections of survival data from patients whose breast
tumors were initially ER+/PR+. Metagenes [71] were
isolated from our T47D microarray dataset representing
each sample (PR-null, WT PR, KR PR; with or without
R5020 treatment). Using Kaplan-Meier survival analysis,
we first compared patient tumors that express PR-
related metagenes (WT or KR, -/+R5020) to all other
patient tumors. This analysis revealed that patients in
this tumor cohort whose tumors expressed any PR gene
signature (that is, indicative of transcriptionally active
PRs) experienced significantly reduced distant metastasis
free survival (P = 0.000785; Figure 5C). Notably, patient
tumors that did not express a PR-related metagene (Fig-
ure 5C, top curve) were associated with approximately
80% long-term survival. Presumably, tumors in this
group expressed abundant PR, but these receptors
remained relatively inactive. Consistent with this notion,
high PR mRNA levels were associated with good out-
come [29]. Our findings suggest that classification of
tumors based on PR expression (rather then activity) is
misleading. Interestingly, patients whose tumor gene sig-
nature resembled that of T47D cells expressing KR
+R5020 trended toward poorer outcome (P < 0.1). To
include the contribution of LI (KR) PR target genes, we
combined patients whose tumors expressed both KR
metagenes (KR -R5020 or KR +R5020). These patients
experienced significantly reduced distant metastasis free
survival relative to those whose tumors did not express
either of the two KR metagenes (P = 0.0261) (Figure
5D). With respect to node and grade, there was no
apparent association with expression of the metagenes.
These data suggest that PR-dependent transcription, and
in particular, the actions of the deSUMOylated (phos-
pho-Ser294) receptor, contribute to rapid tumor pro-
gression and poor outcome in a subset of (luminal)
breast cancer patients.
Discussion
In this study, we performed gene expression profiling to
understand better how PR SUMO modification impacts
transcriptional activity and promoter selection. Using
newly engineered breast cancer cell line models, we
identified a (deSUMOylated) PR-driven gene signature
that is present in human tumors and associated with
decreased patient survival. Previously, we showed that
PR phosphorylation at Ser294 antagonizes PR SUMOy-
lation at Lys388 [13]. Our novel data suggest that breast
cancer cells may utilize this mechanism to shift PR tran-
scriptional action toward target genes that drive cell
proliferation and pro-survival pathways (Figures 4 and
5). Using bioinformatics to analyze global gene expres-
sion levels (Figure 1), we identified dramatic differences
in transcriptional responses between WT and
deSUMOylated PRs [See Additional file 5] that were
further characterized by ChIP analysis as alterations in
promoter/enhancer selectivity (Figure 3, Additional file
7). Additionally, treatment of unmodified breast cancer
cells (or cells expressing only WT PR-B) with EGF
further implicated PR Ser294 phosphorylation (PR
deSUMOylation) in transcriptional derepression of
selected PR target genes (Figure 2). Notably, genes spe-
cifically upregulated by SUMO-deficient PR (that is,
phospho-PR driven) are significantly associated with
genes that are highly expressed in ERBB2-positive
human breast tumors and cell lines; our studies support
a mechanistic link between phosphorylated (deSUMOy-
lated) PR-B-specific transcriptional action and expres-
sion of a subset of ERBB2-associated genes (Figure 5).
Collectively, our data provide a strong rationale for
further study into mechanisms of phospho-PR-depen-
dent regulation of transcription and the potential contri-
bution of this activity to early or rapid breast cancer
progression towards endocrine resistance.
Gene expression analysis identifies SUMOylation-sensitive
PR target genes
We previously reported that PR SUMOylation is tran-
scriptionally repressive at a limited number of endogen-
ous gene loci, including HBEGF, IRS1, and STC1
[13,16]; all three gene products are known to contribute
to breast cancer cell proliferation [72-74]. In the work
reported here, we performed a comprehensive set of
experiments to measure the regulation of endogenous
PR target genes using current microarray techniques for
whole genome expression profiling in T47D cells
expressing either WT PR or SUMO-deficient mutant
K388R PR (phospho-mimic), treated with or without the
synthetic progestin, R5020. Apart from our investigation
of the role of reversible PR SUMOylation, this microar-
ray dataset provides an updated well-controlled analysis
(using newly created vector matched cell lines) of WT
PR-B transcriptional action in response to progestin
treatment. Rigorous independent experiments were per-
formed using additional cell lines and novel cell line
clones expressing either constitutive (stable) or inducible
WT or mutant PRs, and gene expression levels were
measured using distinct microarray platforms (Illumina
and Affymetrix). Indeed, our analysis confirmed 70% of
previously identified PR target genes [21,22] but also
uncovered hundreds of novel PR target genes; many of
these are LI examples [See Additional file 6}. This data-
set will provide a powerful resource for future studies
investigating mechanisms of LD and LI PR-mediated
transcriptional regulation.
Notably, our comparison of genes regulated by WT
versus KR PRs revealed considerable overlap suggesting
that the majority of PR regulated genes are relatively
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insensitive to dynamic modification of PR-B by SUMOy-
lation/deSUMOylation (Figure 1D-E, green and red
Venn categories). However, within these categories,
many genes displayed intermediate (varied) levels of
expression when regulated by either WT or KR PR, sug-
gesting that multiple mechanisms impact PR mediated
transcription, in part according to PR SUMOylation sta-
tus. Conversely, smaller subsets of genes were highly
sensitive to the SUMOylation-status of PR (Figure 1D-E,
blue, yellow, purple and orange Venn categories). Sur-
prisingly, these subsets included genes that were both
up and downregulated by KR PR relative to WT con-
trols, suggesting that SUMOylation of PR-B can be
either repressive or activating, depending on the promo-
ter context. For example, while many proliferative genes
were increased, a number of known tumor suppressor
genes were repressed by deSUMOylated (KR) PR; this is
a topic for further study.
Based on our previous studies [13,16], we predicted
that phospho-Ser294-PRs (that is, that are primarily
deSUMOylated) mediate a shift in gene regulation that
profoundly affects cancer cell phenotypes. Thus, our
goal in the current study was to identify these genes and
understand the mechanism(s) of their differential regula-
tion (by WT and KR PR) using entirely new breast can-
cer cell models. In cells stably expressing S294A PR, a
receptor unable to be phosphorylated on Ser294 and
thus heavily SUMOylated [13,41], the expression of
selected KR-upregulated genes (for example, MSX2 and
so on) was entirely blocked; transcriptional upregulation
was rescued in cells expressing the PR K388R/S294A
double mutant (KRSA; Figure 2C). These data demon-
strate that PR SUMO modification dominantly represses
transcription at PR target genes that are effectively
‘derepressed’ in response to phosphorylation events. For
example, PR-dependent MSX2 and RGS2 mRNA expres-
sion was greatly augmented upon EGF treatment of
cells expressing WT PR (Figure 2D). We conclude that
PR phosphorylation and deSUMOylation affects global
gene expression patterns by dramatically altering PR
transcriptional activity and promoter selectivity in breast
cancer cells.
Mechanisms impacting PR promoter selectivity
Our microarray studies clearly demonstrate that PR
SUMO modification alters the expression of a broad
range of PR target genes but has no effect on others.
Little is known about the mechanisms of promoter
selectivity. However, this question has been addressed
with regard to other SR family members [75]. SR inter-
actions with chromatin are highly dynamic and occur as
a rapid and continuous exchange [76]. Thus, concen-
trated regions of transcription factor ‘binding’ (as mea-
sured by ChIP) actually reflect a shift in the equilibrium
towards increased transcription factor occupancy at that
region. Multiple factors may influence this equilibrium,
such as SR binding to consensus DNA sequences, parti-
cipation of coregulatory factors within multi-protein
complexes and/or sequestration of SRs to specific cellu-
lar locations, as well as histone modifications that regu-
late chromatin accessibility. Additionally, studies of
restriction enzymes have revealed mechanisms that facil-
itate enzyme binding to consensus sequences up to
1,000 times faster than is possible via diffusion alone,
suggesting the existence of ancillary factors that facili-
tate binding [77]. Similarly, recent work has determined
that specific proteins called ‘pioneer factors’ aid in chro-
matin remodeling and localization of SR transcription
factors to nearby genomic binding sites (enhancers) in
developmental tissue or cancer specific settings [78-80].
Modification of protein substrates by the addition of
SUMO molecules can influence protein-protein interac-
tions and/or alter protein stability, localization, or tran-
scriptional activity (reviewed in [15]). PR SUMOylation
(at Lys388) most frequently represses PR transcriptional
activity (but can increase it in a promoter dependent
manner; Figure 1FBCL2L11 and DNALI1), and tends to
slow the rate of ligand-dependent PR downregulation
via proteasome mediated turnover [13], but does not
appreciably alter PR location [81]. Numerous genes in
our analyses behaved like MSX2; expression was sub-
stantially upregulated by SUMO-deficient KR PR, but
not WT PR (Figure 2C). Additionally, KR PR occupied
the MSX2 enhancer two to three times more than the
WT receptor (Figure 3B). The finding that increased
levels of KR PR are recruited to this locus and asso-
ciated with increased MSX2 mRNA expression, suggests
that PR SUMOylation (in the context of SUMO-sensi-
tive enhancer regions and chromatin) alters co-factor
interactions that occur at the level of PR DNA binding.
Related to this finding, PIAS3, a PR SUMOylation E3
ligase, directly inhibits PR binding to PRE DNA
sequences in vitro [81]. Thus, PIAS3-mediated SUMO
conjugation to WT (but not KR) PR may prevent effi-
cient receptor binding to selected PRE sequences, thus
subsequently shifting the equilibrium away from PR
occupancy at these loci. How this mechanism might be
sequence specific or promoter specific remains to be
determined.
Promoter structure is likely to be an important deter-
minant of promoter selection by SUMOylated transcrip-
tion factors, including PR. Holmstrom et al. [82] found
that SUMOylated GR requires stable interaction with
DNA containing multiple GR binding sites in order to
efficiently inhibit transcription. Interestingly, GR
SUMOylation also selectively affects the transcriptional
induction of linked endogenous genes [82]. Related to
this finding, recent chromatin modification mapping
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studies have revealed that histone H3 Lys4 mono- and
dimethylation (H3K4me1/2) at enhancers is associated
with transcriptionally active genes [57,83]. Indeed,
regions of transcription factor accessibility to DNA
response elements were first identified as DNase or
MNase hypersensitive sites because these regions were
relatively free from occupied nucleosomes [84].
H3K4me2 is believed to be an epigenetic marker at
functional enhancers that may recruit additional pro-
teins (pioneer factors) to facilitate nucleosome remodel-
ing and accessibility of the region for transcription
factor binding [57]. We have not identified the pioneer
factors for PR recruitment, but in this study, we
observed elevated H3K4 dimethylation at the MSX2
enhancer in cells expressing SUMO-deficient KR PR,
compared to WT PR. In this model, deSUMOylated PR
may preferentially recruit the histone methyltransferase,
MLL2 (that is, to the MSX2 enhancer), resulting in sus-
tained H3K4 dimethylation that allows formation of pro-
ductive transcriptional complexes at active sites that are
normally repressed by SUMOylated receptors.
Finally, DNA binding specificity for SRs is also highly
dependent on sequence composition. Studies investigat-
ing GR demonstrate that single base pair changes in
consensus GRE/PRE sequences can dramatically affect
receptor binding and cofactor interaction [85]. Thus,
DNA itself appears to be a sequence specific allosteric
ligand for SRs, which can directly influence promoter
selectivity and transcriptional consequences. SUMOy-
lated GRs appear to prefer near-perfect consensus GR-
binding sites [82]. Notably, as with PR, site-specific
phosphorylation of GR also alters its promoter prefer-
ence [86]. It is currently unknown whether SUMOylated
versus deSUMOylated PRs differentially recognize differ-
ent PRE sequences (that is, we did not perform ChIP-
seq experiments to identify all PR-binding sites). How-
ever, this seems plausible because SUMO modifications
can dramatically alter substrate protein conformation.
Clearly, deSUMOylated PRs are capable of recruiting
abundant PR coactivators (CBP, MLL2) to enhancer
regions; the more rapid or stable creation of functional
transcriptional complexes may account for the increased
‘sampling’ or use of selected promoters by KR relative to
WT PRs (Figure 3). Our analysis revealed no obvious
global signal(s) that could account for preferential
repression or activation of selected enhancer regions
over others by SUMOylated or deSUMOylated PRs. Stu-
dies to map the WT and KR PR cistromes are on-going.
Clinical implications of deSUMOylated PR gene
expression
Targeting ER function in luminal breast cancers with
selective ER modulators (SERMs, such as tamoxifen)
and/or aromatase inhibitors (for example, anastrozole,
letrozole, or exemestane) is very effective for a majority
of women [87,88]. Indeed, because SR cross-talk with
growth factor signaling pathways is extensive and
tumors tend to progress towards endocrine resistance
under the influence of heightened growth factor signal-
ing, combination therapies targeting both ER and ERBB
receptors enhance progression free survival [89,90]. We
have uncovered a unique set of genes that were upregu-
lated, or derepressed, by deSUMOylated (phospho-
mimic) PR species under both LD (151 genes) and LI
conditions (92 genes) [See Additional file 9]. Elevated
expression of these genes may signify tumors that are
primarily driven by hyperactive phospho-PR (deSUMOy-
lated) species, particularly in cancers characterized by
activated growth factor signaling cascades. For example,
MAPK and CDK2 or CDK4/6 are known drivers of
breast cancer progression that likely induce persistent
PR Ser294 phosphorylation in some breast tumors (Fig-
ure 1A). We predict that patients with luminal-type (ER
+/PR+) breast tumors that express this ‘phospho-PR’
gene signature exist (see Figure 1A and Additional file
9) and that this subset, if identified early, could benefit
from endocrine therapies that include the use of newer
highly selective antiprogestins (that is, ZK 230211, CDB-
4124), perhaps in combination with currently used anti-
estrogens and/or growth factor pathway inhibition.
Indeed, much research has shown that PR is not only a
clinical marker of functional ER expression, but also an
important independent driver of tumor progression
(reviewed in [91]). Notably, as SR+ luminal A-type
tumors progress towards a more aggressive growth fac-
tor-high luminal B-type phenotype, SR expression begins
to decline, starting with PR loss. These poor prognosis
luminal-B-type tumors are often clinically characterized
as ER+/PR-low or null and are more likely to become
endocrine resistant. We showed previously that deSU-
MOylated phospho-PR function as hyperactive receptors
but also turnover rapidly via the ubiquitin-proteasome
pathway (Figure 1Band [41]). In fact, when PR-dependent
transcription peaks, as measured by RT-qPCR of endo-
genous gene readouts (via mRNA levels, as in Figure 5B)
or using reporter genes, PR protein levels are virtually
undetectable [39]. This finding raises the important ques-
tion of whether PR is also hyperactive in a subset of
breast tumors that are clinically defined as PR-low or
null (that is, as generally measured by methods of total
protein detection in clinical settings). Interestingly, breast
tumors are capable of de novo progesterone synthesis, a
process mediated by growth factor-dependent signaling
[92-94]. Tumor-cell (local) production of progesterone
may contribute to sustained PR action (that is, at LD
genes) in more aggressive ER+/PR+ tumors.
Surprisingly, we found that breast cancer cells expres-
sing deSUMOylated phospho-PR drive the expression of
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cell proliferation genes [See Additional file 9], many
directly involved in positive regulation of the ERBB/
MAPK signaling pathway, thus setting up a type of
‘feed-forward’ vicious cycle that is clearly associated
with tumor progression [68,95]. Our data suggest that
phospho-PR may act as a driver of this transition (that
is, tumor progression towards the gain of growth factor-
driven pathways that can precede SR loss) as indicated
by significant similarity to our uniquely defined PR sig-
natures [See Additional file 9]. Our key findings are sup-
ported by available clinical data from the Women’s
Health Initiative and Million Women’s Study showing
that breast tumors that arose in women taking a proges-
tin as part of HRT were more frequent, larger, and of
higher grade relative to control groups [4,96]. Remark-
ably, a recent analysis of these data demonstrated that
estrogen-only HRT may actually protect women from
invasive breast cancer [3,6]. Taken together with the
work of others [97-99], our data support the concept
that targeting PR action in breast cancer patients may
be highly beneficial, especially for patients that become
SERM resistant. Of note, roughly 40% of patients will
initially fail or eventually develop resistance to endocrine
therapies aimed solely at targeting estrogen action; this
represents a large and underserved population.
The intense study surrounding the molecular subtypes
of breast cancer has provided great insights into genetic
characteristics of this heterogeneous cancer [68], but cur-
rent targeted therapies are still focused on a small num-
ber of clinical-pathological markers. While it is true that
knowing the status of various markers (for example, ER,
PR, and HER2) has prognostic value and can inform cur-
rent therapies, measuring mRNA levels for an expanded
number of relevant genes (that is, gene signatures) will
provide more sensitive and specific information regarding
the genetic pathways active in the tumor. This knowledge
could be used to inform clinical decisions, especially
when targeted therapies are considered. Thus, there has
been rapid expansion of prognostic mRNA expression
based assays to classify breast tumors [29,100-102]. How-
ever, currently available prognostic signatures fail to link
changes in gene expression to the molecular drivers pre-
sent in a given tumor. Here, we have identified a PR-
dependent gene signature more likely to characterize
aggressive tumors (Figure 5D, Additional file 9). Our stu-
dies implicate deSUMOylated phospho-PRs as major dri-
vers of this phenotype. Although validation studies in
animal models are required (in progress), our studies
strongly support the use of antiprogestins as valuable
additions to state-of-the-art antiestrogen-based endo-
crine therapies. Identification of patients with PR-driven
tumors (that contain a phospho-PR gene signature) may
allow early intervention aimed at preventing the develop-
ment of endocrine resistance.
Conclusions
We have determined that PR transcriptional action is
more complex than originally thought, insofar as PR are
sensors for mitogenic stimuli whereby phosphorylation
events drive the receptor toward the deSUMOylated state,
resulting in a dramatically altered transcriptional program
that promotes cell proliferation and pro-survival. We have
uncovered a deSUMOylated phospho-PR gene signature
of both known and novel PR target genes that is a marker
of hyperactive PR signaling in breast cancer cell models;
this signature is indeed also present in a subset of patients
with recurrent breast cancer (Figures. 1A and 5D). In
future, this unique signature may provide a valuable prog-
nostic measure for identifying patients whose tumors are
likely to rapidly progress and/or become endocrine-resis-
tant (that is, to estrogen-based therapies).
Additional material
Additional file 1: Genes differentially regulated by wild-type and
SUMO-deficient PR. Gene names and their normalized expression values
from each Venn diagram category (Figure 1D-E) were organized into
different Excel worksheets. Multiple biological sample comparisons were
performed (for example, genes upregulated by both ligand-dependent
WT and KR, green category in Venn diagram); genes with absolute value
log2 fold change > 0.6 (that is, > 1.5 fold up- or down-regulated) and BH
adjusted P < 0.01 are presented in the corresponding Excel worksheets.
In each worksheet, multiple sample comparisons (log2 fold change and
BH adjusted P value) and the log2 normalized intensities are displayed
for each gene. Data were sorted based on the highest expression (log2
fold change) in the specific sample comparison being presented in each
corresponding Excel worksheet (columns highlighted with grey cell
background color). If multiple probe sets represented a single gene, the
probe set with the highest expression value was used in downstream
analyses and other probe sets were removed.
Additional file 2: Creation and validation of isogenic models of
inducible PR expression in T47D cells. (A) Clonal inducible cell lines
were developed as described in the Materials and methods section and
PR protein expression was determined by western blotting after
treatment with inducer molecule AP21967 for two days and R5020 for
one hour. Progestin-dependent PR phosphorylation was measured using
a PR phospho-Ser294 specific antibody. Beta-actin western blotting was
performed as a loading control. Short-term treatment with R5020
demonstrated progestin-dependent PR global phosphorylation (as
indicated by a slight gel upshift in total PR) and equal levels of ligand-
dependent Ser294 phosphorylation. (B) Gene set enrichment analysis
(GSEA) comparison of whole genome expression profiling data sets
derived from two independent model systems and platforms: (i) T47D
cells stably expressing WT and mutant KR PRs (-/+R5020) using the
Illumina HT-12v4 platform and (ii) T47D cells expressing inducible WT or
mutant KR PR (-/+AP21967, -/+R5020) using the Affymetrix U133A 2.0
platform. Genes most upregulated in the Illumina dataset by WT +R5020
(or KR +R5020) appear on the far left (darkest red) and genes most
downregulated by WT +R5020 (or KR +R5020) appear on the far right
side (darkest blue). Using the GSEA application, Affymetrix genes (black
vertical bars) were positioned along the Illumina dataset (from
upregulated to downregulated genes) and the statistical enrichment
score was determined. All the treatment groups between Affymetrix and
Illumina were statistically significant (P < 0.001). (C) Gene expression
levels were validated for two PR target genes (MSX2 and MAP1A) in T47D
cell lines expressing iWT and iKR PR. Cells were treated with AP21967 to
induce PR expression and co-treated with RU486 and/or R5020 before
RT-qPCR gene expression analysis. Data are represented as mean of n =
3 +/- SD.
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Additional file 3: Overlapping lists of PR-dependent target genes
from previously described gene expression microarrays. Excel
workbook comparing previously known PR target genes [21,22] to novel
PR target genes discovered herein. Three different gene lists were
compared using Venn diagram analyses: genes upregulated by WT PR,
upregulated by SUMO-deficient KR PR, or previously known genes
upregulated by WT PR-B. Genes identified herein were upregulated > 1.5
fold BH adjusted P < 0.01. Analyses were performed for genes
upregulated in response to progestin treatment or genes upregulated in
ligand-independent conditions. Analyses of genes downregulated by PR
were omitted (few PR target genes were previously known to be
downregulated by PR-B). Notably, very few ligand-independent PR target
genes have been reported to date [21]. Perhaps not surprisingly, we
observed little overlap between these datasets.
Additional file 4: Relative recruitment of WT and SUMO-deficient PR
molecules to selected PR target gene enhancers. (A) Recruitment of
PR molecules to consensus PRE sequences in upstream promoter/
enhancer regions of RGS2, MAP1A, and PDK4 (following one hour R5020)
was measured by standard ChIP assay in inducible models of T47D cells
expressing WT (iWT) and KR (iKR) receptors. Recruitment of PR to an
intronic region of the HBB gene was included as a negative control. (B)
ChIP assays were performed as in part A, to demonstrate differential PR
recruitment to a RGS2 enhancer in T47D cells stably expressing either WT
or SUMO-deficient (KR) PR. Data are represented as mean of n = 3 +/-
SD.
Additional file 5: Recruitment of phospho-Ser5 and total-RNA
polymerase II to the MSX2 proximal promoter region. (A)
Recruitment of total RNA polymerase II to the MSX2 proximal promoter
region (following one hour R5020) was measured by standard ChIP assay
in inducible models of T47D cells expressing WT (iWT) and KR (iKR)
receptors. (B) ChIP assay was performed as in part A, using an antibody
targeting functionally active RNA polymerase II, as measured by
detection of CTD Ser5 phosphorylation. Data are represented as mean of
n = 3 +/- SD.
Additional file 6: SUMO-deficient PR upregulates genes involved in
cell proliferation determined by Ingenuity Pathway Analysis.
Significant expression (y-axis) of multiple cellular functions (x-axis)
containing genes upregulated by progestin (log2 fold change > 1.0, BH
adjusted P < 0.01; common fold change > 2.0) in cells expressing either
WT or KR PR. Biological pathways that contain a significant number of
upregulated genes display bars above the horizontal line, representing
BH adjusted P < 0.05.
Additional file 7: The ligand-dependent (LD) and ligand-
independent (LI) KR > WT gene signatures. For each gene signature,
the gene names, normalized expression values, and the BH adjusted P
values are provided for all biological samples and sample comparisons.
The LD (151 genes) and LI (92 genes) KR > WT gene signature lists are
provided in whole.
Additional file 8: Breast tumor Oncomine concepts associated with
PR dependent gene signatures. This Excel workbook contains detailed
data produced from the Oncomine analysis described in Figure 5. All
Oncomine breast cancer dataset concepts that were associated with
various gene signatures are provided, including the LD KR > WT gene
signature. Of these, five ERBB2-positive datasets (three tumor and two
cell line) were associated with the LD KR > WT concept (rows shown in
yellow background). For one of these significantly associated concepts, a
table of the overlapping genes present in both the PR-gene signature
concept (LD KR > WT) and the ERBB2-positive associated concept (from
the Bonnefoi et al. dataset [64]) is available. Also, the top 20 genes
presented in the heat map (Figure 5A) are available (shaded with yellow
background), in addition to all other genes from the dataset [64] not
shown in the heat map. This Oncomine dataset [64] is defined as ‘genes
over-expressed in Ductal Breast Carcinoma ERBB2-positive tumors’.
Additional file 9: Detailed antibody and PCR primer set information.
This Excel workbook contains all the antibody information and primers
sets used in RT- and ChIP-qPCR assays.
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